BOLD - CIK 0001782303
The table below shows Boundless Bio, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $9.73M | $10.67M | $12.22M | $12.14M | $14.09M | $14.73M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.74M |
| $4.47M |
| $4.84M |
| $5.20M |
| $4.63M |
| $4.66M |
| Operating income | -$14.47M | -$15.15M | -$17.06M | -$17.34M | -$18.71M | -$19.39M |
| Income tax | - | - | - | - | - | - |
| Net income | -$13.55M | -$13.88M | -$15.68M | -$15.76M | -$16.51M | -$16.98M |
| EPS (diluted) | -$0.60 | -$0.62 | -$0.70 | -$0.71 | -$0.74 | -$0.77 |